Yes, injection site selection does matter when administering glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), or liraglutide (Victoza, Saxenda)
Nearly 80% of employers say GLP-1 use is a major cost driver for their company, per a May Business Group on Health survey
This product is intended for researchers working with peptide identity, purity, stability, and related in-vitro laboratory applications
The animal care and experimental protocols were strictly in line with the Chinese Guidelines for the Care and Use of Laboratory Animals
Counsel patients regarding the risk of MTC with use of Saxenda and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)
Clinical outcome: Mucositis, stomatitis Severe myelosuppression (anaemia, leukopenia, thrombocytopenia) Nephrotoxicity, hepatotoxicity Life-threatening infections, bleeding High-risk groups: Elderly Patients with renal impairment Patients on high-dose methotrexate (oncology use) Concomitant nephrotoxic drugs Advice: Avoid NSAIDs with high-dose methotrexate